Argenx CIDP data ‘looks like a game-changer,’ says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating on Argenx after the company top-line results from ADHERE, the pivotal study evaluating weekly subcutaneous efgartigimod for the treatment of chronic inflammatory demyelinating polyneuropathy. The stock in morning trading is up 31% to $495.98. The data “looks like a game-changer” that will shift the treatment paradigm of this indication, the analyst tells investors in a research note. While current therapies for the treatment of CIDP offer high response rates, they are often associated with intolerable side effects and long infusion times, says Wainwright. It says view, robust efficacy, an easy 30-90 second administration, and a superior tolerability profile will translate into broad uptake of efgartigimod.